Finch Therapeutics announces ulcerative colitis trial for CP101, amends UMN license

Finch Therapeutics Group, Inc.

Investigator-sponsored trial at Brigham and Women's Hospital comparing two doses of CP101 in mild-to-moderate ulcerative colitis; topline data expected in 2025.
Amendment to University of Minnesota license allows Finch to satisfy performance milestones via sublicensing, aligning with new partnership-focused strategy.
Finch exclusively licenses 13 issued patents and 7 patent applications covering human fecal microbe formulations and microbiota diversity methods.
Clinical trial designed to generate data on safety, PK, PD, and clinical efficacy, building on microbiome evidence in ulcerative colitis.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Finch Therapeutics Group, Inc. amended Amended and Restated Exclusive License Agreement with Regents of the University of Minnesota valued at amended terms related to performance milestones, including extension of deadlines and expansion of r (effective 2023-04-12).

Action: amendment
Agreement: license
Counterparty: Regents of the University of Minnesota
Value: amended terms related to performance milestones, including extension of deadlines and expansion of r
Effective: 2023-04-12

Exact text from the filing

On April 12, 2023, Finch Therapeutics Holdings LLC (“FTH”), a direct, wholly owned subsidiary of Finch Therapeutics Group, Inc. (the “Company”), and the Regents of the University of Minnesota (“UMN”), entered into an amendment (the “Amendment”) to the Amended and Restated Exclusive License Agreement, dated January 28, 2022, between FTH and UMN (the “UMN Agreement”).

View on SEC.gov

Browse all material agreements →

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-013276

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.